eli lilly glp-1 medications portfolio weight-loss drug appears to suppress binge-eating signal, small study finds GLP-1 2.0: Where the Next

the study excluded individuals with comorbid neurological, metabolic, genetic or psychiatric conditions, including epilepsy, fragile X syndrome, tuberous sclerosis, PKU, fetal alcohol syndrome and any acute or chronic medical illness

As a graduate of the prestigious New York University (NYU) Medical School, he received his Medical Doctorate (M.D.) with distinguished honors in cell biology research after defending a thesis on vascular stem cell biology

They are also known to cause rare but potentially life-threatening cardiomyopathy

Neill E, Rossell SL, Yolland C, Meyer D, Galletly C, Harris A, et al

Megaloblastic Anemia

As with other GLP-1 receptor medications, theoretical risks include gallbladder disease and, based on animal studies, potential concerns regarding medullary thyroid carcinoma in susceptible individuals